Pages that link to "Item:Q5135528"
From MaRDI portal
The following pages link to A Bayesian seamless phase I–II trial design with two stages for cancer clinical trials with drug combinations (Q5135528):
Displaying 11 items.
- A prospective combination of phase II and phase III in drug development (Q478229) (← links)
- Bayesian phase I/II adaptively randomized oncology trials with combined drugs (Q641145) (← links)
- A Bayesian phase I/II clinical trial design in the presence of informative dropouts (Q1747447) (← links)
- Adaptive designs for drug combination informed by longitudinal model for the response (Q2423165) (← links)
- Phase I (or Phase II) Dose-Ranging Clinical Trials: Proposal of a Two-Stage Bayesian Design (Q4796210) (← links)
- Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents (Q4967095) (← links)
- A Three-Stage Bayesian Adaptive Phase I/II Design and Simulation Studies (Q5417921) (← links)
- Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information (Q6085905) (← links)
- A Bayesian adaptive design for dual-agent phase I-II oncology trials integrating efficacy data across stages (Q6572291) (← links)
- Bayesian dose escalation with overdose and underdose control utilizing all toxicities in phase I/II clinical trials (Q6625365) (← links)
- A nonparametric Bayesian method for dose finding in drug combinations cancer trials (Q6626759) (← links)
